Mulmit

Septerna, Inc.Septerna, Inc.

SEPN Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2025-12-3145,951,000-68,297,000-48,879,000-1.1
2024-12-311,075,000-80,823,000-71,798,000-7.26
2023-12-31151,0002,075,0004,180,0000.29

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-09-01Long Daniel D.SVP, Drug Discovery3,333
2026-09-01Long Daniel D.SVP, Drug Discovery3,333
2026-09-01Long Daniel D.SVP, Drug Discovery3,333
2026-08-12RA CAPITAL MANAGEMENT, L.P.746,500
2026-08-12RA CAPITAL MANAGEMENT, L.P.746,500
2026-08-12Third Rock Ventures V, L.P.147,059
2026-08-12Third Rock Ventures V, L.P.141
2026-08-11Bhatt ElizabethPresident and COO18,681
2026-08-11Bhatt ElizabethPresident and COO6,319
2026-08-11Bhatt ElizabethPresident and COO25,000
2026-08-11Bhatt ElizabethPresident and COO18,681
2026-08-11Bhatt ElizabethPresident and COO6,319

8-K events

FiledItems
2026-08-25Regulation FD disclosure · Other events · Financial statements and exhibits
2026-08-10Results of operations · Financial statements and exhibits
2026-06-30Submission of matters to a vote
2026-05-11Results of operations · Financial statements and exhibits
2026-04-13Regulation FD disclosure · Financial statements and exhibits
2026-03-09Results of operations · Financial statements and exhibits
2026-03-02Regulation FD disclosure · Other events · Financial statements and exhibits
2026-01-12Regulation FD disclosure · Financial statements and exhibits
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…

Pharmaceutical Preparations — 같은 업종, 그리고 규모가 비슷한 기업Pharmaceutical Preparations — and other companies of a similar size

SEC가 같은 업종(Pharmaceutical Preparations)으로 분류한 기업이 먼저 오고, 그다음은 제출된 매출로 가까운 순입니다 — 가장 최근 연간 값이며, 연간 값이 없으면 최근 네 분기 합입니다. Companies the SEC assigns to the same industry (Pharmaceutical Preparations) come first, then the nearest by revenue as filed — the latest annual figure, or the last four quarters where no annual one is filed. 순서일 뿐 값이 싸거나 비싸다는 뜻이 아닙니다.Order only — it does not say a company is cheap or expensive.